Uppsala, Sweden – September 04, 2026 -- Orexo AB has struck a non-binding agreement in principle with the US Department of Justice to settle a federal investigation that has run since 2020, the Swedish pharmaceutical company said.
Orexo to pay $4 million in installments over several years
Under the tentative terms, Orexo would pay USD 4 million in installments spread across multiple years. The company would also accept a capped contingent payment equal to five percent of net sales, triggered only if certain sales thresholds are met in 2030-2031 and contingent on Orexo's commercial products performing well in the market.
Settlement structured as non-prosecution agreement with no admission of wrongdoing
The resolution would take the form of a Non-Prosecution Agreement (NPA) combined with a separate civil settlement, with no admission of wrongdoing by Orexo or any current or former employees. Once finalized, the NPA and civil settlement would close out the DOJ matter entirely, eliminating further exposure for the company related to this investigation.
Two former US employees separately settle civil claims with DOJ
Orexo said two former Orexo US employees have reached their own agreements in principle with the DOJ to resolve civil claims. The company intends to pursue insurance coverage for the full settlement amount tied to these former employees.
CEO cites six years of investigation costs as driver for settlement
Nikolaj Sørensen, President and CEO of Orexo, said the DOJ investigation has been ongoing for more than six years. "The decision to pursue a settlement is not an admission of any wrongdoing, but is based on the significant costs of a continued process and the need to focus on the continued development of Orexo and its important research,